Daily Respiratory Research Analysis
Analyzed 229 papers and selected 3 impactful papers.
Summary
Analyzed 229 papers and selected 3 impactful articles.
Selected Articles
1. Inhaled Antibiotics to Treat Ventilator-Associated Pneumonia: A Systematic Review and Meta-Analysis.
Across 32 RCTs, adjunctive inhaled antibiotics improved clinical cure and microbiological eradication in ventilator-associated pneumonia and were associated with lower mortality in VAP-only populations. Compared with IV therapy, inhaled routes may shorten ventilator duration and reduce nephrotoxicity, without clear effects on ICU length of stay.
Impact: This comprehensive synthesis with advanced methods addresses a long-debated ICU therapy and shows clinically meaningful benefits, potentially informing updates to VAP management guidelines.
Clinical Implications: Consider adjunctive inhaled antibiotics for culture-confirmed or strongly suspected VAP, especially when targeting Gram-negative pathogens, using optimized delivery systems and stewardship oversight.
Key Findings
- Adjunctive inhaled antibiotics improved clinical cure versus placebo/blank (RR 1.24; 95% CI 1.07–1.43).
- All-cause mortality was reduced overall (RR 0.84; 95% CI 0.71–0.98) and notably in VAP-only cohorts (RR 0.77; 95% CI 0.65–0.90).
- Microbiologic eradication increased (RR 1.42; 95% CI 1.27–1.58) and emergence of new drug resistance decreased (RR 0.20; 95% CI 0.06–0.64).
- Compared with IV antibiotics, inhaled routes shortened ventilator duration by ~2.1 days and reduced nephrotoxicity.
Methodological Strengths
- PRISMA-guided meta-analysis with GRADE certainty assessments and trial sequential analysis.
- Primary analyses restricted to RCTs with sensitivity analyses including non-RCTs and meta-regression to identify effect modifiers.
Limitations
- Heterogeneity in nebulizer systems, drug choices, and dosing regimens across trials.
- Limited data for direct comparisons versus IV therapy and for patient-centered outcomes (e.g., quality of life).
Future Directions: Conduct pragmatic, device-standardized RCTs focusing on patient-centered outcomes, optimal agent-selection for MDR pathogens, and ecological impacts on resistance.
OBJECTIVES: To assess the effects of adjunctive inhaled antibiotics in treating ventilator-associated pneumonia (VAP). DATA SOURCES: We searched PubMed, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov through May 31, 2025. STUDY SELECTION: We included randomized controlled trials (RCTs) and nonrandomized studies comparing adjunctive inhaled antibiotics with placebo/blank or IV antibiotics for VAP treatment. DATA EXTRACTION: Two groups independently screened studies, extracted data, and assessed risk of bias. Analyses used random effects models. Subgroup analyses, meta-regression, trial sequential analysis, and the Grading of Recommendations Assessment, Development, and Evaluation were performed. DATA SYNTHESIS: We included 32 RCTs in the primary analysis and 41 non-RCTs in sensitivity analysis. Compared with placebo/blank, inhaled antibiotics significantly improved clinical cure (16 RCTs; n = 1425; risk ratio [RR], 1.24; 95% CI, 1.07-1.43) and reduced all-cause mortality (21 RCTs; n = 1855; RR, 0.84; 95% CI, 0.71-0.98), with consistent findings in sensitivity analyses including non-RCTs. These benefits were significant in VAP-only patients (clinical cure: 11 RCTs; n = 775; RR, 1.29; 95% CI, 1.10-1.52 and all-cause mortality: 15 RCTs; n = 1152; RR, 0.77; 95% CI, 0.65-0.90), but not in studies including mixed pneumonia populations. Meta-regression confirmed VAP-only population as a significant effect modifier. Inhaled antibiotics also improved microbiological eradication (20 RCTs; n = 1805; RR, 1.42; 95% CI, 1.27-1.58) and reduced emergence of new drug resistance (four RCTs; n = 182; RR, 0.20; 95% CI, 0.06-0.64). No differences were found in ICU length of stay, ventilator duration, or other adverse events. Compared with IV antibiotics, inhaled antibiotics shortened ventilator duration (three RCTs; n = 322; mean difference, -2.11 d; 95% CI, -3.73 to -0.49 d), and reduced nephrotoxicity (three RCTs; n = 292; RR, 0.42; 95% CI, 0.26-0.68). CONCLUSIONS: Compared with placebo/blank, adjunctive inhaled antibiotics improve clinical cure and microbiological eradication, and may reduce mortality, particularly in VAP-only patients. Exploratory analyses based on limited data suggest potential advantages over IV therapy, including shorter ventilator duration and lower nephrotoxicity, warranting further high-quality trials.
2. Effect of energy-efficient homes on residents' health: evidence from a natural experiment in the Netherlands.
Using a staggered difference-in-differences design on 2 million residents over ~10 years, housing retrofits (insulation and mechanical ventilation) modestly reduced respiratory medication use, especially among children. Antihistamine use declined by 1.87% overall; pediatric respiratory medications declined by 3.76%, with a 6.91% reduction in asthma medications at 5 years (borderline significance). No significant effects were seen for non-respiratory outcomes.
Impact: This is rigorous, policy-relevant evidence that built-environment interventions can measurably improve respiratory health at population scale, especially for children. It informs health–energy policy integration and prioritization of vulnerable groups.
Clinical Implications: Clinicians and public health teams can advocate for housing retrofits as part of asthma and allergy prevention strategies, especially in children. Health systems may consider cross-sector programs linking energy-efficiency upgrades with respiratory health outcomes.
Key Findings
- Antihistamine use declined by 1.87% (95% CI 0.19–3.55) after retrofits.
- Among children <18 years, respiratory medication use decreased by 3.76% (1.04–6.48).
- Pediatric asthma medication use decreased by 6.91% at 5 years (p=0.051).
- No significant changes were observed in non-respiratory outcomes or total health-care costs.
Methodological Strengths
- Large-scale natural experiment with staggered difference-in-differences and individual fixed effects over ~12 million person-years.
- Objective outcomes from insurer prescription data; robust assignment mechanism unrelated to health outcomes.
- National scope with long observation window (2012–2021).
Limitations
- Medication use is a proxy and may not capture clinical severity or diagnoses.
- Generalizability may be limited to public housing and specific retrofit packages.
- Residual confounding cannot be fully excluded despite robust design.
Future Directions: Link housing interventions with clinical outcomes (exacerbations, hospitalizations), indoor air quality metrics, and cost‑effectiveness; stratify by comorbidities and socioeconomic vulnerability to optimize targeted policies.
BACKGROUND: Many governments around the world subsidise upgrades to poorly insulated homes, yet the extent to which these energy-efficiency improvements reduce health risks remains unclear. We aimed to provide the first large-scale evidence on whether such retrofits lower the use of respiratory health-care services, particularly for children and other vulnerable individuals. METHODS: We leveraged a large-scale natural experiment in which public housing units across the Netherlands were retrofitted between 2012 and 2021. Upgrades included insulation and mechanical ventilation and were implemented in homes eligible on the basis of poor energy efficienc
3. Integrating deep learning of low-dose computed tomography with clinical data for lung cancer risk prediction.
Across 22,469 participants (52,482 LDCT series) from four screening programs, the integrated Sybil‑Epi model improved 6‑year lung cancer risk prediction (AUC 0.83 vs 0.80 for Sybil), especially when nodules were absent (AUC 0.76 vs 0.64). Short‑term prediction remained strongest (AUC 0.93 at 1 year), with decreasing performance over time.
Impact: Demonstrates clinically meaningful gains by augmenting imaging AI with routinely available clinical-epidemiologic data, addressing a known limitation of image-only models for long-horizon risk and nodule-absent scans.
Clinical Implications: Enables more precise long-horizon risk stratification within LDCT screening, potentially informing interval selection, adjunct testing, and resource allocation—especially for individuals without visible nodules.
Key Findings
- Sybil achieved AUC 0.93 at year 1, decreasing to 0.79 at year 6 in independent cohorts.
- Sybil‑Epi improved 6‑year AUC to 0.83 (95% CI 0.81–0.85) vs Sybil 0.80 (0.78–0.82).
- When nodules were absent, Sybil‑Epi AUC was 0.76 (0.70–0.82) vs Sybil 0.64 (0.57–0.70).
- Dataset included 22,469 participants and 52,482 LDCT series across four screening programs.
Methodological Strengths
- External validation across three independent screening cohorts with large sample size.
- Pre-specified stratification by nodule presence/size; rigorous comparative benchmarking vs existing model.
- Longitudinal performance assessment over 1–6 years.
Limitations
- Retrospective design; prospective clinical utility and workflow impact not yet tested.
- Performance still lower at long horizons and with small/absent nodules despite improvement.
- Generalizability beyond participating programs requires further validation.
Future Directions: Prospective impact studies integrating Sybil‑Epi into screening workflows, calibration across diverse populations, cost‑effectiveness, and hybrid strategies combining AI risk, biomarkers, and smoking history.
BACKGROUND: Low-dose computed tomography (LDCT) screening reduces lung cancer mortality, the leading cause of cancer deaths globally. Segmentation-free deep learning (DL) models such as Sybil can improve screening efficiency but require extensive validation and possible improvement. RESEARCH QUESTION: Can the integration of deep learning based on LDCT scans and clinical data improve lung cancer risk prediction? STUDY DESIGN AND METHODS: Retrospective cohort data from 4 different screening programs, one used for model training and three for external validation. Data collected between the years 2002 and 2021. The median follow-up period was 7 years. All participants had a histor